3-Ethoxy-5,6-dibromosalicylaldehyde
Based on 1 Customer Validation
3-Ethoxy-5,6-dibromosalicylaldehyde is an IRE1/ERN1 inhibitor, with an IC50 of 0.12 μM, a Ki of 71-88 nM, and a Kd of 100 nM against the ribonuclease activity of hIRE1α, as well as an IC50 of 4.8 μM against yeast Ire1. It shows selectivity toward IRE1 ribonuclease. 3-Ethoxy-5,6-dibromosalicylaldehyde blocks the IRE1/ERN1-mediated unfolded protein response (UPR) signaling pathway, including XBP-1 mRNA splicing, induction of XBP1 target genes, and activation of MAPK8/9/10, but does not alter the phosphorylation level of IRE1α or the PERK/ATF6 pathway. 3-Ethoxy-5,6-dibromosalicylaldehyde inhibits chikungunya virus replication, induces growth arrest, apoptosis and clonogenic inhibition in pancreatic cancer cells, reduces FB1 (Fumonisin B1) (HY-N6719)-induced autophagy and cell death, regulates PGG-induced senescence and apoptosis, and alleviates Sorafenib (HY-10201)-induced vacuolization and damage in hepatic stellate cells. 3-Ethoxy-5,6-dibromosalicylaldehyde can be used in research related to chikungunya virus infection, pancreatic cancer, FB1-induced nephrotoxicity, liver cancer, breast cancer, lung cancer and liver fibrosis.
For research use only. We do not sell to patients.
- Purity : 99.97%
- CAS No.: 20041-64-9
- Formula: C9H8Br2O3
- Molecular Weight:323.97
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
All Arrestin Isoforms
More
Biological Activity
Description
|
IRE1α 0.12 μM (IC50) |
IRE1α 71-88 nM (Ki) |
IRE1α 100 nM (Kd) |
yeast Ire1 4.8 μM (IC50) |
ERN1 |
XBP-1 |
p38 MAPK |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MIA PaCa-2 | IC50 |
0.4 μM
|
Antiproliferative activity against human MiaPaCa2 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human MiaPaCa2 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| Panc1005 | IC50 |
76.2 μM
|
Antiproliferative activity against human Panc1005 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human Panc1005 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| Panc203 | IC50 |
1.5 μM
|
Antiproliferative activity against human Panc0203 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human Panc0203 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| SU.86.86 | IC50 |
9.8 μM
|
Antiproliferative activity against human SU8686 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human SU8686 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| PANC-03-27 | IC50 |
25.6 μM
|
Antiproliferative activity against human Panc0327 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human Panc0327 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| PANC-1 | IC50 |
23.5 μM
|
Antiproliferative activity against human Panc1 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human Panc1 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| ASPC1 | IC50 |
6.3 μM
|
Antiproliferative activity against human AsPc1 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human AsPc1 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
| BXPC-3 | IC50 |
1.1 μM
|
Antiproliferative activity against human BxPc3 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
Antiproliferative activity against human BxPc3 pancreatic cancer cells assessed as reduction in cell viability by MTT assay.
|
24952679 |
In Vitro
3-Ethoxy-5,6-dibromosalicylaldehyde (DBSA) (30 μM; 4-48 h) inhibits the IRE1 pathway in HEK293 cells, as shown by reduced Xbp1s gene expression and phospho-IRE1 protein levels when used at 30 μM for 4 h (with Tunicamycin (HY-A0098)) or 48 h (with chikungunya virus)[1].
3-Ethoxy-5,6-dibromosalicylaldehyde (30 μM; 48 h post-infection) suppresses chikungunya virus replication in HEK293 cells when used at 30 μM for 48 h post-infection, as shown by reduced viral E1 gene and protein expression[1].
3-Ethoxy-5,6-dibromosalicylaldehyde (3ETH) (1 nM-100 μM) inhibits proliferation of a panel of human pancreatic cancer cell lines with IC50 values ranging from 0.4 μM to 76.2 μM, and is active against HNA-resistant cell lines including AsPc1, BxPc3, and PL45[2].
3-Ethoxy-5,6-dibromosalicylaldehyde (1-10 μM; 14 days) inhibits clonogenic growth of MiaPaCa2 and Panc0403 human pancreatic cancer cells in soft agar[2].
3-Ethoxy-5,6-dibromosalicylaldehyde (1 μM; 24 hours) up-regulates TXNIP mRNA and down-regulates TXN mRNA in Panc0403 and MiaPaCa2 human pancreatic cancer cells[2].
3-Ethoxy-5,6-dibromosalicylaldehyde (60 μM; 24 h) suppresses PGG-induced senescence-like growth arrest in HepG2, MCF-7, and A549 cells, as shown by reduced SA-β-gal-positive cell percentages[5].
3-Ethoxy-5,6-dibromosalicylaldehyde (100 nM-20 μM; 3 min) binds directly and selectively to purified human IRE1α-cyto with a Kd of ~100 nM, and does not bind to RNase A[6].
Pre-treatment of LX2 and HSC-T6 hepatic stellate cells with 3-Ethoxy-5,6-dibromosalicylaldehyde (10 μM; 60 min pre-incubation prior to 12-24 h Sorafenib treatment) reduces and delays Sorafenib-induced cytoplasmic vacuolation[7].
3-Ethoxy-5,6-dibromosalicylaldehyde potently and selectively inhibits the endoribonuclease activity of human and yeast IRE1α without affecting autophosphorylation, blocks chemically induced XBP1 splicing and XBP1 target gene induction in cultured cell lines, and binds specifically, reversibly, and dose-dependently to IRE1α[3].
3-Ethoxy-5,6-dibromosalicylaldehyde potently inhibits the endoribonuclease activity of purified human IRE1α-cyto with an IC50 of ~0.12 μM via a non-competitive mechanism relative to the mini-XBP-1 RNA substrate[6].
3-Ethoxy-5,6-dibromosalicylaldehyde (0.48-60 μM; 1 h) inhibits yeast Ire1 endoribonuclease activity with an IC50 of 6 μM, which is 50-fold less potent than its activity against human IRE1α-cyto[6].
3-Ethoxy-5,6-dibromosalicylaldehyde (5-120 μM; 2 h) dose-dependently inhibits DTT (DL-Dithiothreitol) (HY-15917)-induced XBP-1 splicing in human MM1.s myeloma cells, with complete inhibition at high concentrations[6].
Pre-treatment of LX2 and HSC-T6 hepatic stellate cells with 3-Ethoxy-5,6-dibromosalicylaldehyde (EDBS) (10 μM; 60 min pre-incubation prior to 12-24 h Sorafenib treatment) suppresses Sorafenib-induced activation of the IRE1α-XBP1s ER stress/UPR pathway by reducing protein expression of IRE1α, GRP78, XBP1s, and calreticulin[7].
3-Ethoxy-5,6-dibromosalicylaldehyde directly inhibits IRE1α endoribonuclease activity by covalently binding to lysine K907, dose-dependently reducing Xbp1 splicing in human cell lines without altering other UPR pathways[8].
3-Ethoxy-5,6-dibromosalicylaldehyde (DBS) (50 μM; 48 h) inhibits FB1-induced MAPK8/9/10 activation, autophagy, and subsequent cell death in MARC-145 monkey kidney cells[4].
3-Ethoxy-5,6-dibromosalicylaldehyde (60 μM; 24 h) inhibits PGG-induced autophagosome formation in HepG2 cells, as indicated by a reduced LC3-II/ACTB ratio of 0.08 compared to 0.36 with PGG alone[5].
3-Ethoxy-5,6-dibromosalicylaldehyde (24 h) enhances PGG-induced cell death in HepG2 and MCF-7 cells after 48 h of combined treatment[5].
Pre-treatment of LX2 hepatic stellate cells with 3-Ethoxy-5,6-dibromosalicylaldehyde (10 μM; 60 min pre-incubation prior to 12-24 h Sorafenib treatment) drastically reduces Sorafenib-induced non-apoptotic cell death at 12 h and 24 h post-treatment[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Panc0403, MiaPaCa2
-
Concentration:1 μM
-
Incubation Time:24 hours
-
Result:Up-regulated TXNIP mRNA expression by 13-fold in Panc0403 cells.
Up-regulated TXNIP mRNA expression by 7-fold in MiaPaCa2 cells.
Down-regulated TXN mRNA expression to 50% of control levels in Panc0403 cells.
Down-regulated TXN mRNA expression to 45% of control levels in MiaPaCa2 cells.
-
Cell Line:African green monkey kidney MARC-145 cells
-
Concentration:50 μM (co-treated with 20 μM FB1)
-
Incubation Time:48 h
-
Result:Significantly decreased FB1-induced MAPK8/9/10 phosphorylation.
Reduced the FB1-induced conversion of LC3-I to LC3-II, with LC3-II/ACTB ratio dropping from 0.58 to 0.18.
Dramatically reduced FB1-induced cell death.
-
Cell Line:HepG2
-
Concentration:60 μM (in combination with 25 μM PGG)
-
Incubation Time:24 h
-
Result:Significantly reduced the PGG-induced conversion of LC3-I to LC3-II.
Decreased the LC3-II/ACTB ratio from 0.36 to 0.08.
-
Cell Line:activated human hepatic stellate cell line LX2, activated rat hepatic stellate cell line HSC-T6
-
Concentration:10 μM (pre-incubated for 60 min prior to 10 μM Sorafenib treatment for 12 h); 10 μM (pre-incubated for 60 min prior to 10 μM Sorafenib treatment for 24 h)
-
Incubation Time:12 h (post-Sorafenib treatment); 24 h (post-Sorafenib treatment)
-
Result:Significantly reduced Sorafenib-induced upregulation of IRE1α, GRP78 (BiP), XBP1s, and calreticulin proteins in LX2 cells at 12 h post-Sorafenib treatment.
Suppressed Sorafenib-induced expression of IRE1α, GRP78 (BiP), XBP1s, and calreticulin proteins in LX2 cells at 24 h post-Sorafenib treatment.
Suppressed Sorafenib-induced IRE1α overexpression in HSC-T6 cells at 12 h and 24 h post-Sorafenib treatment.
Caused only a marginal reduction in basal phosphorylated IRE1α (pIRE1α) levels in LX2 cells at 12 h post-Sorafenib treatment.
-
Cell Line:activated human hepatic stellate cell line LX2
-
Concentration:10 μM (pre-incubated for 60 min prior to 10 μM Sorafenib treatment for 12 h); 10 μM (pre-incubated for 60 min prior to 10 μM Sorafenib treatment for 24 h)
-
Incubation Time:12 h (post-Sorafenib treatment); 24 h (post-Sorafenib treatment)
-
Result:Drastically reduced the PI-positive cell population in LX2 cells at both 12 h and 24 h post-Sorafenib treatment.
Reduced PI-positive cell population from 45.5% (Sorafenib alone) to 12.7% (Sorafenib plus target reagent) at 12 h post-Sorafenib treatment.
Reduced PI-positive cell population from 61.2% (Sorafenib alone) to 24.2% (Sorafenib plus target reagent) at 24 h post-Sorafenib treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice[2]
-
Dosage:20 mg/kg
-
Administration:i.p.; three times weekly; 4 weeks
-
Result:Reduced mean tumor weight to 70% of control tumors.
Chemical Information
-
CAS No. 20041-64-9
-
Appearance Solid
-
Molecular Weight 323.97
-
Formula C9H8Br2O3
-
Color White to yellow
-
SMILES
O=CC1=C(O)C(OCC)=CC(Br)=C1Br
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (308.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (298 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Agrawal N, et al. Pharmacological Manipulation of UPR: Potential Antiviral Strategy Against Chikungunya Virus. Indian journal of microbiology. 2022 Dec;62(4):634-640. [Content Brief]
[2]. Chien W, et al. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget. 2014 Jul 15;5(13):4881-94. [Content Brief]
[6]. Volkmann K, et al. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. The Journal of biological chemistry. 2011 Apr 08;286(14):12743-55. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0867 mL | 15.4335 mL | 30.8671 mL | 77.1676 mL |
| 5 mM | 0.6173 mL | 3.0867 mL | 6.1734 mL | 15.4335 mL | |
| 10 mM | 0.3087 mL | 1.5434 mL | 3.0867 mL | 7.7168 mL | |
| 15 mM | 0.2058 mL | 1.0289 mL | 2.0578 mL | 5.1445 mL | |
| 20 mM | 0.1543 mL | 0.7717 mL | 1.5434 mL | 3.8584 mL | |
| 25 mM | 0.1235 mL | 0.6173 mL | 1.2347 mL | 3.0867 mL | |
| 30 mM | 0.1029 mL | 0.5145 mL | 1.0289 mL | 2.5723 mL | |
| 40 mM | 0.0772 mL | 0.3858 mL | 0.7717 mL | 1.9292 mL | |
| 50 mM | 0.0617 mL | 0.3087 mL | 0.6173 mL | 1.5434 mL | |
| 60 mM | 0.0514 mL | 0.2572 mL | 0.5145 mL | 1.2861 mL | |
| 80 mM | 0.0386 mL | 0.1929 mL | 0.3858 mL | 0.9646 mL | |
| 100 mM | 0.0309 mL | 0.1543 mL | 0.3087 mL | 0.7717 mL |